Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03619655 · ClinicalTrials.gov registry record · Phase 1
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03619655 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 3 participants.
The verdict
NCT03619655, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The study is an open label, non-randomized study designed to evaluate the diagnostic performance of SPECT CT.
Interventions
- PROCEDURE SPECT CT
- DRUG 18F-DCFPyL PET/CT
- DRUG 18F-NaF PET/CT
- PROCEDURE WB-MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2022-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03619655
The ClinicalTrials.gov registry entry for NCT03619655 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which SPECT CT is the first listed.
NCT03619655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03619655 about?
NCT03619655 is a clinical study titled "Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy". The study is an open label, non-randomized study designed to evaluate the diagnostic performance of SPECT CT.
What is the current status of trial NCT03619655?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-11-15. Estimated completion is 2022-11-14.
What interventions are being tested in trial NCT03619655?
The interventions under investigation include: SPECT CT (PROCEDURE), 18F-DCFPyL PET/CT (DRUG), 18F-NaF PET/CT (DRUG), WB-MRI (PROCEDURE).
Who is sponsoring clinical trial NCT03619655?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.